Comparison of Simeprevir vs. Telaprevir in HCV Genotype 1 Non-Responders

The ATTAIN study compared simeprevir and telaprevir in previous non-responders with genotype 1 HCV. The study included 379 patients with simeprevir and 384 with telaprevir, focusing on SVR12 as the primary endpoint. Baseline characteristics, treatment regimens, patient disposition, and virologic out

0 views • 6 slides